Stock Market Reviews

Read and share opinions on QNRX (Quoin Pharmaceuticals, Ltd.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

Latest News

• Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies
  Nov 11, 2025
• Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025
  Oct 30, 2025
• Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
  Oct 21, 2025
• Top Midday Gainers
  Oct 10, 2025
• Quoin Pharmaceuticals Shares Jump After Announcing $104.5 Million Private Placement
  Oct 10, 2025
• Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million
  Oct 10, 2025
• Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome
  Sep 9, 2025
• Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome
  Aug 21, 2025
• Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy
  Aug 18, 2025
• Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton
  Aug 12, 2025
• QNRX: Recent FDA & EMA Designations for QRX003 Potentially Could Accelerate Timeline
  Aug 7, 2025
• Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025
  Jul 31, 2025
• Quoin Pharmaceuticals Provides Product Portfolio Update
  Jul 29, 2025
• Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases
  Jun 26, 2025
• Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
  Jun 24, 2025
• QNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand Further
  May 28, 2025
• Quoin Pharmaceuticals Says US FDA Clears Second Netherton Syndrome Pivotal Study
  May 22, 2025